Ritsner Polypharmacy in Psychiatry Practice, Volume II

Use of Polypharmacy in the "Real World"
1. Auflage 2013
ISBN: 978-94-007-5799-8
Verlag: Springer Netherland
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 321 Seiten

Reihe: Biomedical and Life Sciences

Although monotherapy is generally recommended as the treatment of choice, treatment resistance of patients with psychosis, cognitive, mood and anxiety disorders represents a significant clinical problem. In this context, augmentation and combination strategies are commonly employed to address this problem. Although multiple medication use common in psychiatric practice, reasons, efficacy and safety for polypharmacy, and augmentative strategies have remained unclear. It remains unclear if there is an evidence base to support polypharmacy. Furthermore, excessive and inappropriate use of psychotropic medications has been recognized as a public health problem. This volume is the first comprehensive, clinically oriented, reference on the multiple medication use to treat psychotic, cognitive, mood and anxiety disorders.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Ritsner, Michael S

Inhaltsverzeichnis

1. Antipsychotic polypharmacy for schizophrenia: 'Secret sauce' or 'wild abandon'?.- Antipsychotic polypharmacy in USA.- Antipsychotic polypharmacy in Czech Republic and in Ukraine.- Antipsychotic polypharmacy in residential facilities in Italy: the gap between recommendations and real world practice.- Antipsychotic polypharmacy and associated phenomena in patients with schizophrenia: Rational or irrational?.- Antipsychotic polypharmacy in schizophrenia. How to counteract this common practice?.- Clozapine combinations in treatment-resistant schizophrenia patients.- Metabolic syndrome and antipsychotic polypharmacy.- Evidence based combination therapy for bipolar disorder.- Antidepressant combination strategies for major depressive disorder.- Herbal remedies and nutraceuticals as augmentation or adjunct for mood and anxiety disorders: evidence for benefit and risk.- Obsessive-compulsive syndromes in schizophrenia: A case for polypharmacy?.- Polypharmacy and potentially inappropriatemedication use among elders with dementia.- The role of polypharmacy in bipolar disorder treatment guidelines.